Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

Condition:   Gastroenteritis NorovirusInterventions:   Other: Placebo;   Biological: Norovirus GII.4 Challenge Pool CIN-1Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)Not yet recruiting - verified January 2015

Source: ClinicalTrials.gov - January 8, 2015 Category: Research Source Type: clinical trials